Turkish Thoracic Journal
Original Article

The Use of High-Flow Nasal Oxygen Therapy in the Management of Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Feasibility Study

1.

Department of Pulmonary Medicine, and Intensive Care, Trakya University, Faculty of Medicine, Edirne,Turkey

2.

Department of Internal Medicine, and Intensive Care, Hacettepe University Faculty of Medicine, Ankara, Turkey

3.

Department of Internal Medicine and Intensive Care, Turkish Ministry of Health Haseki Education and Research Hospital, İstanbul, Turkey

Turk Thorac J 2019; 1: -
DOI: 10.5152/TurkThoracJ.2022.21268
Read: 58 Downloads: 21 Published: 01 July 2022

OBJECTIVE: This study investigated the efficacy of high-flow nasal oxygen therapy in patients with severe acute exacerbation of chronic obstructive pulmonary disease admitted to the intensive care unit.

MATERIAL AND METHODS: Totally, 23 patients were enrolled in the study. High-flow nasal oxygen therapy was administered with a predefined protocol. Vital signs, Visual Analog Scale for dyspnea, and arterial blood gas parameters were recorded at the beginning under low-flow oxygen support therapy and the 1st, 6th, 12th, and 24th hours of high-flow nasal oxygen therapy. High-flow nasal oxygen therapy duration, intensive care unit length of stay, and intensive care unit, in-hospital, and 60-day mortality were recorded as outcomes and compared according to the presence of pneumonia upon admission.

RESULTS: In 12 patients (52.2%), pneumonia was present. High-flow nasal oxygen therapy was applied for a median of 57 hours [49.2-104.5]. Overall decreases were detected in heart rate (P = .001), respiratory rate (P < .001), and Visual Analog Scale for dyspnea (P = .001) during the first 24 hours of the therapy. Although there was an increase in PaCO2 (P = .001), pH increased (P < .001) over time too. No change in partial arterial oxygen pressure (P = .63) and partial arterial oxygen pressure/fraction of inspired oxygen ratio (P = .22) was noted. Nineteen patients (77%) were successfully weaned from high-flow nasal oxygen therapy. While the high-flow nasal oxygen therapy failure rate was 23%, the in-hospital and 60-day mortality rates were 8.6%. Outcomes were not different between patients with and without pneumonia.

CONCLUSION: High-flow nasal oxygen therapy was efficient in relieving respiratory distress and well-tolerated with no adverse out- come in severe acute exacerbation of chronic obstructive pulmonary disease patients admitted to the intensive care unit.

Cite this article as: Hancı P, Öcal S, Kıvanç Kaya E, Topeli A. The use of high-flow nasal oxygen therapy in the management of severe acute exacerbation of chronic obstructive pulmonary disease: A feasibility study. Turk Thorac J. 15 June 2022 10.5152/ TurkThoracJ.2022.21268.

Files
EISSN 2149-2530